Cartesian Therapeutics, Inc. RNAC 深 沪
等待开盘 03-26 09:30:00 美东时间
6.18
+0.110
+1.81%
华盛通- 最 高6.40
- 今 开6.21
- 成交量 9.84万股
- 最 低 6.11
- 昨 收 6.07
- 总市值 1.64亿
- 52周最高 15.57
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 5.98
- 委 比 -99.08%
- 总股本 2650.90万
- 历史最高 840.00
- 量 比 1.04
- 振 幅 4.78%
- 历史最低 5.98
- 每 手 1
- 风险率 2.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
美股牛股 | 医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%
医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%，获诺和诺德授权销售其减肥药；QURE大涨26%，FDA疫苗负责人将离职，有分析称监管政策或转向灵活>>
03-10 16:46
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Cartesian Therapeutics shares are trading higher after the company reported its Q4 financial results.
Cartesian Therapeutics shares are trading higher after the company reported its...
03-10 00:41
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
03-10 00:24
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over losses of $(0.40) per
03-09 19:58
Insights into Cartesian Therapeutics Q4 Earnings
Cartesian Therapeutics (NASDAQ:RNAC) just disclosed its Q4 earnings on Monday, ...
03-09 19:44
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.
01-09 23:55
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
01-07 02:42
